

RECEIVED
OPPT CBIC

Sanitized Copy

2015 APR -8 AM 11:12

April 7, 2015

Via Federal Express

TSCA Confidential Business Information Center (7407M)
EPA East - Room 6428 Attn: Section 8(e)
U.S. Environmental Protection Agency
1201 Constitution Avenue, NW
Washington, DC 20004-3302

CBIC Control Number

364608

Page | 1

Subject: Notice in Accordance with TSCA Section 8(e): Results of a Test Study in Female, Non-Pregnant Wistar Rats (Range Finding, Oral Administration – Gavage)

Dear Section 8(e) Coordinator:

[REDACTED] is submitting results of a Test Study in Female, Non-Pregnant Wistar Rats [CrI:WI(HAN)] with [REDACTED], conducted by [REDACTED]. The test substance is an experimental pesticide.

The test substance was planned to be administered once per day to groups of 3 female Wistar rats via gavage for a maximum of 14 days. All animals were assessed by gross pathology.

The dose levels of the test substance were 100 and 500 mg/kg bw/d.

The following most relevant findings were observed:

500 mg/kg bw/d

- Two animals found dead (at day 1 of the study)
- One animal was sacrificed in a moribund state at day 3 of the study
- Severe clinical findings i.e. abdominal position (3/3), unsteady gait (1/3), semiclosed eyelid (1/3)
- Body weight loss from study day 0 to 3

100 mg/kg bw/d

- One animal found dead (at day 8 of the study)
- One animal was sacrificed in a moribund state at day 8
- Severe clinical findings i.e. abdominal position (2/3), lateral position (1/3), unsteady gait (2/3), semiclosed eyelid (1/3), reduced nutritional condition (1/3), respiration accelerated and/or labored (1/3)
- Significantly decreased food consumption from study day 0 to 7 (-36.7%)
- Body weight loss from study day 0 to 7
- Ulceration in stomach (1/3)
- Discolored lungs (1/3)
- Entire intestine empty (1/3)

The study is ongoing.

Sanitized Copy

TSCA Confidential Business Information Center (7407M)

April 7, 2015

██████████ understands that reporting of results from this study under TSCA 8(e) is in accordance with EPA's policy.

Please note that a confidential version of this letter is enclosed, treating the chemical identity and company identity as Confidential Business Information.

Page | 2

A Confidentiality Substantiation Questionnaire is being submitted.

Sincerely,